Novartis Ag

University of Pennsylvania

University of Pittsburgh

Harvard College

Dana-farber-cancer Institute Inc.

Intellia Therapeutics, Inc.

Jennifer Brogdon

Andreas Loew

Carl H June

Saar Gill

Marco Ruella

David Jonathan Glass

Joan Mannick

Leon Murphy

Michael C Milone

Qilong Wu

Boris Engels

Lu Huang

Ming Lei

John Scholler

Yongqiang Wang

Brian Walter Granda

Jimin Zhang

Na Li

Marcela V Maus

Reshma Singh

Barbara Brannetti

Hilmar Erhard Ebersbach

John Trauger

Li Zhou

Carla Guimaraes

Jiquan Zhang

Saad Kenderian

Kurt Alex Heldwein

William Dole

David L Porter

Chonghui Zhang

Celeste Richardson

Elena Orlando

Hans Bitter

Igor Splawski

Hideho Okada

Jennifer Bordeaux

Huijuan Song

Thai Tran

Naveen Kumar Dakappagari

Ju Young Kim

William Raj Sellers

Laura Alexandra Johnson

John Hastewell

Eugene Choi

Heather Huet

Gabriela Plesa

Regina M Young

Steven Highfill

Joshua Goldstein

Gordon James Freeman

Gerhard Johann Frey

Hwai Wen Chang

Arlene Helen Sharpe

Glenn Dranoff

Jennifer Marie Mataraza

Michael D Kalos

Brian Edward Vash

Jan Weiler

Julia Neugebauer

Lai Wei

Qiumei Yang

Julia Jascur

Yuting Tang

Annika Schmid

Thomas Huber

Abhishek Garg

John C Byrd

Tony Fleming

Mariusz Wasik

Natarajan Muthusamy

Avery D Posey

Morag Helen Stewart

Aida Abujoub

Connie Hong

Jan J Melenhorst

John Blankenship

Brian Holmberg

Amy Jo Johnson

Felipe Bedoya

Jason A Dubovsky

Yi Yang

Dexiu Bu

Deborah A Knee

Fei Wang

Xu Zhu

Michael R Greene

Carla Patricia Pinto Guimaraes

Daniela Cipolletta

Corin Dorfmeier

Nicholas Wilcox

Joseph Fraietta

Jihyun Lee

Hyungwook Lim

Ming-Wei Chen

Sarah Hesse

Andrew Marc Stein

Akash Sohoni

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain

Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

The present disclosure is directed to genome editing systems, reagents and methods for immunooncology.

Compositions and methods for immunooncology

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

Sortase molecules and methods described herein allow for the construction of a CAR or CAR member, e.g., in situ, on a CARX, e.g., CART, cell. For example, sortase mediated transfer of an antigen binding domain, e.g., a scFv, onto a CAR member having a sortase acceptor motif in place of an antigen binding domain can provide for a complete CAR member on a cell wherein the cell does not comprise nucleic acid that encodes the complete CAR member.

Sortase synthesized chimeric antigen receptors

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Anti-BCMA chimeric antigen receptor

Growing community of inventors

Sudbury, MA, United States of America

Jennifer Brogdon